The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
作者信息
Hernández-Boluda Juan-Carlos, Pereira Arturo, Gómez Montse, Boqué Concepción, Ferrer-Marín Francisca, Raya José-María, García-Gutiérrez Valentín, Kerguelen Ana, Xicoy Blanca, Barba Pere, Martínez Jesús, Luño Elisa, Alvarez-Larrán Alberto, Martínez-López Joaquín, Arbelo Elisa, Besses Carles
出版信息
Haematologica. 2014 Apr;99(4):e55-7. doi: 10.3324/haematol.2013.101733. Epub 2014 Jan 31.
Abstract
摘要
相似文献
1
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.国际预后评分系统不能准确区分原发性血小板增多症后和真性红细胞增多症后骨髓纤维化患者的不同风险类别。
Haematologica. 2014 Apr;99(4):e55-7. doi: 10.3324/haematol.2013.101733. Epub 2014 Jan 31.
2
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.原发性骨髓纤维化和真性红细胞增多症后/或原发性血小板增多症后骨髓纤维化患者接受芦可替尼治疗的临床表现、结局和预后模型的差异。一项大型多中心研究中 MYSEC-PM 的新视角。
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
3
4
[Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化中国患者的预后因素分析
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):876-880. doi: 10.3760/cma.j.issn.0253-2727.2016.10.012.
5
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.真性红细胞增多症或原发性血小板增多症转化为骨髓纤维化或急性髓系白血病患者的异基因造血干细胞移植：欧洲血液与骨髓移植组慢性恶性肿瘤工作组MPN小组委员会的报告
Haematologica. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. Epub 2014 Jan 3.
6
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化的诊断标准建议：骨髓纤维化研究与治疗国际工作组的共识声明
Leukemia. 2008 Feb;22(2):437-8. doi: 10.1038/sj.leu.2404914. Epub 2007 Aug 30.
7
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.异基因造血干细胞移植治疗原发性血小板增多症和真性红细胞增多症后骨髓纤维化。
Intern Med. 2020;59(16):1947-1956. doi: 10.2169/internalmedicine.4375-19. Epub 2020 Aug 15.
8
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化的真实世界临床特征。
Ann Hematol. 2024 Jan;103(1):97-103. doi: 10.1007/s00277-023-05528-4. Epub 2023 Nov 10.
9
Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.动态国际预后评分系统与原发性骨髓纤维化继发于 PV 和 ET 预后模型在异基因造血干细胞移植后对真性红细胞增多症和原发性血小板增多症骨髓纤维化结局预测的比较。
Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.
10
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.真性红细胞增多症后骨髓纤维化患者与原发性和原发性血小板增多症后骨髓纤维化患者相比，可能会经历更高的血栓形成风险。
Leuk Res. 2022 Aug;119:106905. doi: 10.1016/j.leukres.2022.106905. Epub 2022 Jun 21.
引用本文的文献
1
Fedratinib in 2025 and beyond: indications and future applications.2025年及以后的费德拉替尼：适应症与未来应用
Blood Adv. 2025 Apr 22;9(8):1907-1915. doi: 10.1182/bloodadvances.2024015365.
2
C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms.C-甘露糖基色氨酸是骨髓增生性肿瘤血小板增多症的新型生物标志物。
Sci Rep. 2024 Aug 14;14(1):18858. doi: 10.1038/s41598-024-69496-z.
3
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.日本继发性骨髓纤维化的全国性前瞻性调查：作为生存风险模型，动态国际预后评分系统升级版（DIPSS-plus）优于骨髓增殖性肿瘤国际预后评分系统（MYSEC-PM）
Blood Cancer J. 2023 Jul 19;13(1):110. doi: 10.1038/s41408-023-00869-9.
4
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.如何管理异体干细胞移植候选患者的骨髓纤维化。
Cells. 2022 Feb 5;11(3):553. doi: 10.3390/cells11030553.
5
Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants.费城染色体阴性骨髓增殖性肿瘤的进展：病理问题与分子决定因素概述
Cancers (Basel). 2021 Nov 4;13(21):5531. doi: 10.3390/cancers13215531.
6
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.基因表达谱与骨髓纤维化患者的分子和临床特征相关。
Blood Adv. 2021 Mar 9;5(5):1452-1462. doi: 10.1182/bloodadvances.2020003614.
7
Standard care and investigational drugs in the treatment of myelofibrosis.骨髓纤维化治疗中的标准护理与研究性药物。
Drugs Context. 2019 Sep 26;8:212603. doi: 10.7573/dic.212603. eCollection 2019.
8
Mutational profiling in myelofibrosis: implications for management.骨髓纤维化中的突变分析：对治疗的影响。
Int J Hematol. 2020 Feb;111(2):192-199. doi: 10.1007/s12185-019-02758-z. Epub 2019 Oct 19.
9
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.JAK抑制剂时代异基因干细胞移植在骨髓纤维化中的作用：基于病例的综述
Bone Marrow Transplant. 2020 Apr;55(4):708-716. doi: 10.1038/s41409-019-0683-1. Epub 2019 Sep 18.
10
Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and as a potential tumor suppressor gene that is epigenetically regulated.骨髓纤维化的表观基因组分析揭示了增强子元件中广泛的 DNA 甲基化变化，以及作为潜在的肿瘤抑制基因，其受到表观遗传调控。
Haematologica. 2019 Aug;104(8):1572-1579. doi: 10.3324/haematol.2018.204917. Epub 2019 Jan 17.
本文引用的文献
1
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
2
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
3
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.原发性骨髓纤维化中整体无白血病生存的精细化细胞遗传学危险度分类：433 例患者的单中心研究。
Leukemia. 2011 Jan;25(1):82-8. doi: 10.1038/leu.2010.234. Epub 2010 Oct 14.
4
Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.在原发性骨髓纤维化死亡和急变相竞争风险的时间依赖性预后因素的随访中进行鉴定：对 172 例患者的研究。
Blood. 2010 Jun 3;115(22):4350-5. doi: 10.1182/blood-2009-12-255943. Epub 2010 Mar 22.
5
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.原发性或真性红细胞增多症/原发性骨髓纤维化后骨髓纤维化患者 12 个月内死亡的预测动态模型。
J Clin Oncol. 2009 Nov 20;27(33):5587-93. doi: 10.1200/JCO.2009.22.8833. Epub 2009 Sep 28.
6
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.真性红细胞增多症后骨髓纤维化：116例患者中该并发症的发生率及危险因素
Br J Haematol. 2009 Sep;146(5):504-9. doi: 10.1111/j.1365-2141.2009.07804.x. Epub 2009 Jul 8.
7
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.JAK2V617F突变状态和等位基因负荷对真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的临床表型和预后影响很小。
Haematologica. 2009 Jan;94(1):144-6. doi: 10.3324/haematol.13721. Epub 2008 Nov 27.
8
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.基于骨髓纤维化研究与治疗国际工作组的一项研究的原发性骨髓纤维化新预后评分系统。
Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6.
9
Risk factors for leukemic transformation in patients with primary myelofibrosis.原发性骨髓纤维化患者白血病转化的危险因素。
Cancer. 2008 Jun 15;112(12):2726-32. doi: 10.1002/cncr.23505.
10
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.一种预测真性红细胞增多症后骨髓纤维化患者生存情况的动态预后模型。
Blood. 2008 Apr 1;111(7):3383-7. doi: 10.1182/blood-2007-11-121434. Epub 2008 Jan 10.
Zotero 插件